Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hong kong trial tests 'Through the Gate' program to cut reoffending

NCT ID NCT07593534

Recruiting now Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a social work program called Project ReBond for people serving their first or second prison sentence in Hong Kong. The program includes workshops and counseling before release, plus support like job help and mentoring after release. Researchers will track 300 participants for 13 months to see if the program reduces reoffending compared to standard services.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Desistance-based social work intervention
What this could lead to
If successful, this program could provide an effective way to reduce reoffending and support former prisoners in rebuilding their lives.
What could go wrong
This is a relatively small trial (300 people) in one city, so results may not apply elsewhere. The study relies on self-reported reoffending, which may not be fully accurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECIDIVISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Recidivism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECIDIVISM

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong Island, 000, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.